BKM Wealth Management LLC Sells 537 Shares of Sanofi $SNY

BKM Wealth Management LLC cut its holdings in Sanofi (NASDAQ:SNY) by 5.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,821 shares of the company’s stock after selling 537 shares during the period. BKM Wealth Management LLC’s holdings in Sanofi were worth $474,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of SNY. Ameritas Advisory Services LLC purchased a new stake in shares of Sanofi in the 2nd quarter worth $28,000. Accent Capital Management LLC bought a new stake in Sanofi during the first quarter valued at about $29,000. Eastern Bank increased its position in Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after buying an additional 300 shares in the last quarter. Banque Transatlantique SA bought a new position in shares of Sanofi in the first quarter worth about $33,000. Finally, Golden State Wealth Management LLC lifted its position in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after buying an additional 545 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SNY. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $56.00 to $58.00 in a report on Monday, September 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Finally, JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $62.67.

Sanofi Trading Up 1.2%

Sanofi stock opened at $50.62 on Friday. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The firm’s 50 day moving average price is $48.49 and its 200-day moving average price is $49.60. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The stock has a market cap of $124.30 billion, a P/E ratio of 12.17, a PEG ratio of 1.23 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.Sanofi’s revenue was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.73 EPS. On average, equities analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.